BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 23938765)

  • 1. BRAF and KIT somatic mutations are present in amelanotic melanoma.
    Massi D; Pinzani P; Simi L; Salvianti F; De Giorgi V; Pizzichetta MA; Mirri F; Steffan A; Orlando C; Santucci M; Canzonieri V
    Melanoma Res; 2013 Oct; 23(5):414-9. PubMed ID: 23938765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B; Akalin T; Kandiloğlu G
    Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amelanotic acral melanomas: clinicopathological, BRAF mutation, and KIT aberration analyses.
    Choi YD; Chun SM; Jin SA; Lee JB; Yun SJ
    J Am Acad Dermatol; 2013 Nov; 69(5):700-707. PubMed ID: 23972510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amelanotic/hypomelanotic melanoma: clinical and dermoscopic features.
    Pizzichetta MA; Talamini R; Stanganelli I; Puddu P; Bono R; Argenziano G; Veronesi A; Trevisan G; Rabinovitz H; Soyer HP
    Br J Dermatol; 2004 Jun; 150(6):1117-24. PubMed ID: 15214897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
    Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
    Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amelanotic Malignant Melanoma with a BRAF V600E Mutation Mimicking Primary Lung Cancer.
    Matsuzawa R; Morise M; Tanaka I; Hayai S; Tamiya Y; Koyama J; Hase T; Wakahara K; Kim D; Shimoyama Y; Hashimoto N
    Intern Med; 2022 Mar; 61(5):703-708. PubMed ID: 34433708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF V600E mutation-specific antibody: A review.
    Ritterhouse LL; Barletta JA
    Semin Diagn Pathol; 2015 Sep; 32(5):400-8. PubMed ID: 25744437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods.
    O'Brien O; Lyons T; Murphy S; Feeley L; Power D; Heffron CCBB
    J Clin Pathol; 2017 Nov; 70(11):935-940. PubMed ID: 28424234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological and molecular study of penile melanoma.
    Oxley JD; Corbishley C; Down L; Watkin N; Dickerson D; Wong NA
    J Clin Pathol; 2012 Mar; 65(3):228-31. PubMed ID: 22011445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymph node metastases of melanoma: challenges for BRAF mutation detection.
    Chen G; Dudley J; Tseng LH; Smith K; Gurda GT; Gocke CD; Eshleman JR; Lin MT
    Hum Pathol; 2015 Jan; 46(1):113-9. PubMed ID: 25456393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.
    Hugdahl E; Kalvenes MB; Puntervoll HE; Ladstein RG; Akslen LA
    Br J Cancer; 2016 Mar; 114(7):801-8. PubMed ID: 26924424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
    Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
    Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of BRAF, NRAS and c-KIT mutation status between tumor tissues and autologous tumor cell-lines of stage III/IV melanoma.
    Knol AC; Pandolfino MC; Vallée A; Nguyen F; Lella V; Khammari A; Denis M; Puaux AL; Dréno B
    Exp Dermatol; 2015 Jan; 24(1):70-3. PubMed ID: 25363723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry.
    Bruno W; Martinuzzi C; Andreotti V; Pastorino L; Spagnolo F; Dalmasso B; Cabiddu F; Gualco M; Ballestrero A; Bianchi-Scarrà G; Queirolo P; Grillo F; Mastracci L; Ghiorzo P;
    Oncotarget; 2017 Jan; 8(5):8069-8082. PubMed ID: 28039443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands.
    van Engen-van Grunsven AC; Küsters-Vandevelde HV; De Hullu J; van Duijn LM; Rijntjes J; Bovée JV; Groenen PJ; Blokx WA
    Gynecol Oncol; 2014 Jul; 134(1):10-4. PubMed ID: 24802725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between two widely used laboratory methods in BRAF V600 mutation detection in a large cohort of clinical samples of cutaneous melanoma metastases to the lymph nodes.
    Jurkowska M; Gos A; Ptaszyński K; Michej W; Tysarowski A; Zub R; Siedlecki JA; Rutkowski P
    Int J Clin Exp Pathol; 2015; 8(7):8487-93. PubMed ID: 26339422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: implications on optimized targeted therapy.
    Saroufim M; Habib RH; Gerges R; Saab J; Loya A; Amr SS; Sheikh S; Satti M; Oberkanins C; Khalifeh I
    Exp Mol Pathol; 2014 Dec; 97(3):315-20. PubMed ID: 25236573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wilms tumor gene 1 (WT1), TP53, RAS/BRAF and KIT aberrations in testicular germ cell tumors.
    Boublikova L; Bakardjieva-Mihaylova V; Skvarova Kramarzova K; Kuzilkova D; Dobiasova A; Fiser K; Stuchly J; Kotrova M; Buchler T; Dusek P; Grega M; Rosova B; Vernerova Z; Klezl P; Pesl M; Zachoval R; Krolupper M; Kubecova M; Stahalova V; Abrahamova J; Babjuk M; Kodet R; Trka J
    Cancer Lett; 2016 Jul; 376(2):367-76. PubMed ID: 27085458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
    Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
    Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
    Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
    J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.